Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 86 of 331 for:    DONEPEZIL

Effects of Cholinergic Augmentation on Measures of Balance and Gait

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02206620
Recruitment Status : Unknown
Verified July 2014 by John G. Nutt, Oregon Health and Science University.
Recruitment status was:  Recruiting
First Posted : August 1, 2014
Last Update Posted : August 1, 2014
Sponsor:
Collaborator:
Michael J. Fox Foundation for Parkinson's Research
Information provided by (Responsible Party):
John G. Nutt, Oregon Health and Science University

Brief Summary:

This study will compare the effects of placebo and donepezil, a drug that helps conserve concentrations of the neurotransmitter, acetylcholine on measures of balance and gait in subjects with Parkinson's disease (PD). This study is a double-blind, placebo controlled, cross-over randomized clinical trial. Short-latency afferent inhibition (SAI), a physiological index of cholinergic function will be measured to determine if the deficits in balance and gait correlate with abnormalities of the SAI and if SAI is altered by donepezil as a measure of drug efficacy. Cognitive tests like the attention network test will be administered to determine if changes in gait and balance are mediated by changes in attention.

The results of this study will be the most direct test of the hypothesized role of cholinergic neurons and the neurotransmitter, acetylcholine in terms of gait and balance. The study is exploratory because it is not known whether donepezil will affect gait, balance or attention, nor which measures of gait, balance or attention will be sensitive to drug manipulation. The study's immediate goal is to determine the potential utility of cholinergic manipulation as a strategy for preventing or treating balance and gait dysfunction in PD. The findings of this trial are intended to lead to more sharply focused questions about the role of cholinergic neurons in balance and gait and eventually to Phase II B trials to determine clinical utility of cholinergic manipulation to prevent falls and improve mobility.


Condition or disease Intervention/treatment Phase
Parkinson's Disease Drug: Donepezil Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effects of Cholinergic Augmentation on Measures of Balance and Gait
Study Start Date : July 2014
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Donepezil
Donepezil 5 mg per day for week 1-3 or 12-14. 10 mg/day for weeks 4-6 or 14-18, if tolerated.
Drug: Donepezil
Other Name: Aricept

Placebo Comparator: Placebo
Placebo 5 mg per day for week 1-3 or 12-14. 10 mg/day for weeks 4-6 or 14-18, if tolerated.
Drug: Donepezil
Other Name: Aricept




Primary Outcome Measures :
  1. Examine the effects of a cholinesterase inhibitor, donepezil, on postural standing sway with and without a dual cognitive task. [ Time Frame: Up to four years ]
    Increased body sway while standing and enhancement of the sway by dual tasking are markers for increased risk of falling in Parkinson's disease. Sway will be measured with an inertial sensor attached to the waist.

  2. Variability of step length while walking and its increase with dual tasking [ Time Frame: Four years ]
    Variability in step length and an increase with dual tasking is another marker for increased fall risk in Parkinson' disease. This step length or duration ariability will be measured with inertial sensors attached to both feet.


Secondary Outcome Measures :
  1. Examine the effects of a cholinesterase inhibitor, donepezil, on physiological markers of mobility associated with falls in PD (postural sway in stance and gait variability). [ Time Frame: Up to four years ]
    The second marker: increased gait variability and augmentation with dual-tasking.

  2. Short-latency afferent inhibition is a marker of cortical cholinergic activity [ Time Frame: Four years ]
    Short-latency afferent inhibition by a peripheral stimulation is a transcranial magnetic stimulation method to evaluate cortical cholinergic activity. Short-latency afferent Inhibition will be used to determine if our subjects with Parkinson's disease have evidence of reduced cholinergic tone which correlates with their measures of postural and gait instability. Also changes in short-latency afferent inhibition with donepezil will be a measure of pharmacological efficacy of donepezil.

  3. Attention Network Test [ Time Frame: Four years ]
    Attention Network Test (ANT) is 15 minute computerized test or reaction times with various cues and targets designed to assess alerting, orienting and executive control of attention. Deficits of attention are related to fall risk and may be affected by donepezil.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 30 years old or older
  • Diagnosis of idiopathic Parkinson's disease
  • Stand unassisted (without use of an assistance device) and walk continuously for at least 2 minutes.

Exclusion Criteria:

  • musculoskeletal disorders that affect standing and walking
  • Uncorrected vision disturbance
  • Vestibular problems
  • Major depression
  • Hallucinations or other psychiatric disturbances
  • Tachycardia
  • Bradycardia
  • Arrhythmias
  • Peptic ulcer disease
  • Use of anticholinergics
  • Use of cholinesterase inhibitors
  • Use of bladder antispasmodics
  • Use of tricyclic antidepressants

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02206620


Locations
Layout table for location information
United States, Oregon
Oregon Health & Science University Recruiting
Portland, Oregon, United States, 97239-3098
Contact: Andrew Fraser, BS    503-418-4387    frasean@ohsu.edu   
Principal Investigator: John Nutt, MD         
Sponsors and Collaborators
Oregon Health and Science University
Michael J. Fox Foundation for Parkinson's Research
Investigators
Layout table for investigator information
Principal Investigator: John Nutt, M.D. Oregon Health and Science University

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: John G. Nutt, M.D., Oregon Health and Science University
ClinicalTrials.gov Identifier: NCT02206620     History of Changes
Other Study ID Numbers: 9437
First Posted: August 1, 2014    Key Record Dates
Last Update Posted: August 1, 2014
Last Verified: July 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Donepezil
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Cholinergic Agents
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents